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a  b  s  t  r  a  c  t
Derquantel  (DQL),  a  semi-synthetic  member  of  a novel  anthelmintic  class,  the  spiroin-
doles,  in combination  with  abamectin  (ABA)  [as  the  combination  product  STARTECT®] is
a new  entry  for  the  treatment  and  control  of  parasites  in  sheep.  The  19  studies  reported
herein  were  conducted  in Australia,  New  Zealand,  South  Africa  and  the  United  Kingdom
to  demonstrate  the efﬁcacy  of  derquantel–abamectin  (DQL–ABA)  against  a broad  spec-
trum  of  gastrointestinal  and  respiratory  nematodes  of  sheep,  and  to support  registration
of the combination  product.  Eleven  studies  were  conducted  using  natural  or experimental
parasite  infections  with  unknown  or  unconﬁrmed  resistance,  while  eight  studies  utilised
isolates/strains  with  conﬁrmed  or well  characterised  resistance  to one  or more  currently
available  anthelmintics,  including  macrocyclic  lactones.  All  studies  included  DQL–ABA  and
negative control  groups,  and  in  selected  studies  one  or more  reference  anthelmintic  groups
were included.  In  all  studies  the  commercial  formulation  of  DQL–ABA  was  administered
orally  at  2 mg/kg  DQL  and  0.2  mg/kg  ABA;  placebo  was  administered  in  the  same  volume  as
DQL–ABA; and  reference  anthelmintics  were  administered  as  per  label  recommendations,
except  in  one  instance  where  levamisole  was  administered  at twice  the label  dose.  Infection,
necropsy, worm  collection  and  worm  counting  procedures  were  performed  using  stan-
dard techniques.  Efﬁcacy  was  calculated  based  on the percentage  reduction  in  geometric
mean worm  count  relative  to  negative  control  for each  nematode  species  and  lifecycle  stage
targeted. Twenty-two  isolates/strains  used  in  the eight  studies  targeting  resistant  worms
had proven  resistance:  three  to  one  anthelmintic  class,  eleven  to  two  classes  and  eight to
three or  more  classes;  of these  resistant  strains,  16  demonstrated  resistance  to a macro-
cyclic  lactone  anthelmintic.  Regardless  of resistance  status  in  the  19  studies,  DQL–ABA
controlled  a  broad  range  of  economically  important  gastrointestinal  and  respiratory  nema-
tode parasites  of sheep,  as  follows:  ≥98.9%  efﬁcacy  against  Haemonchus  contortus  (adult
ia  circumcincta  (adult,  L4  and  hypobiotic  L4); Teladorsagia  trifurcata  (L4);and L4);  Teladorsag∗ Corresponding author. Tel.: +61 3 8388 4378; fax: +61 3 8388 4381.
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Trichostrongylus  axei  (adult  and  L4);  Trichostrongylus  colubriformis  (adult  and  L4);  Tri-
chostrongylus  falculatus  (adult);  Trichostrongylus  rugatus  (adult);  Trichostrongylus  vitrinus
(adult  and  L4);  Cooperia  curticei  (adult  and  L4);  Cooperia  oncophora  (adult  and  L4);  Nema-
todirus  spathiger  (adult);  Nematodirus  battus  (adult);  Nematodirus  spp.  (hypobiotic  L4);
Strongyloides  papillosus  (adult);  Strongyloides  spp.  (L4);  Chabertia  ovina  (adult);  Oesophagos-
tomum  venulosum  (adult);  Dictyocaulus  ﬁlaria  (adult);  and  Protostrongylus  rufescens  (adult);
≥97.0%  efﬁcacy  against  Trichuris  ovis  (adult);  and  ≥95.9%  efﬁcacy  against  T.  trifurcata  (adult).
Derquantel–abamectin  is  a  highly  effective  combination  anthelmintic,  which  will  provide
an  important  new  tool  for controlling  helminths  of  sheep  when  used  in conjunction  with
ing  prasustainable  drench
1. Introduction
Treatment with broad-spectrum anthelmintics has
been  the cornerstone of internal parasite control in
small ruminants for the last 50 years. However, the
reliance on anthelmintics has driven rapid development
of anthelmintic resistance following the introduction of
new  anthelmintic classes to the market. For each new
class, resistance has developed in at least one impor-
tant nematode species of sheep (and goats) within a
few  years of introduction (Kaplan, 2004; McKellar and
Jackson, 2004). The continuous stream of new classes
(modes-of-action) of anthelmintics had for several decades
compensated for parallel development of resistance (von
Samson-Himmelstjerna and Blackhall, 2005); however,
from the introduction of ivermectin in the early 1980s
until the recent discovery of the amino-acetonitrile deriva-
tives  and identiﬁcation of monepantel as an anthelmintic
(Ducray et al., 2008; Kaminsky et al., 2008a,b), over a
quarter of a century had elapsed before a chemical class
with  a new mode-of-action was developed for use in live-
stock.  Additional chemistries with novel modes-of-action
are urgently needed to control nematodes in small rumi-
nants  as available products, including combinations, are
failing  (Besier, 2007).
Derquantel  (DQL), also known as 2-desoxopara-
herquamide, 2-deoxyparaherquamide and PNU-141962
(Lee et al., 2002), is a semi-synthetic member of a new
anthelmintic class, the spiroindoles. This class includes
natural products with known anthelmintic activity, e.g.,
paraherquamide (Yamazaki et al., 1981; Ostlind et al.,
1990;  Shoop et al., 1990; Blanchﬂower et al., 1991) and
the  marcfortines (Lee et al., 2001, 2002; Mauragis et al.,
2002;  Johnson et al., 2004). The spiroindoles are char-
acterised by an indole or oxindole moiety fused with a
carbocycle, more speciﬁcally a cyclopentyl ring, at the
spiro  quaternary carbon atom at position C-3 of the indole.
Derquantel was identiﬁed through a spiroindole medici-
nal  chemistry program, and this work has been reported
elsewhere (Lee et al., 2001, 2002; Mauragis et al., 2002;
Johnson et al., 2004). The chemical structure of DQL is
shown in Fig. 1. Derquantel and the other spiroindole
anthelmintics are nicotinic cholinergic antagonists, which
block  cation channels in nematode muscle cell membranes.
This novel mode-of-action blocks cholinergic neuromus-
cular transmission, rapidly inducing ﬂaccid paralysis in
parasitic  nematodes in vitro (Robertson et al., 2002; Zinser
et  al., 2002).ctices.
© 2011 Elsevier B.V. 
The  efﬁcacy of DQL against gastrointestinal nema-
todes of sheep was  assessed early in its development,
and in subsequent dose-determination studies; in the
dose  range tested (0.5–8.0 mg/kg), DQL was found to be
a  mid-spectrum anthelmintic. At the dose rate selected
for the combination product, derquantel alone was  consis-
tently  found to have excellent anthelmintic activity (>95%
reduction in mean worm count) against the adult and
fourth larval (L4) stages of Trichostrongylus and Nema-
todirus spp., and the adult stage of Haemonchus contortus;
it  demonstrated variable efﬁcacy (≤95%) against Telador-
sagia (=Ostertagia) circumcincta, the L4 of H. contortus, and
some  large intestinal nematodes (PR Little and SJ Maeder,
unpublished data).
Derquantel  has been developed as an oral anthelmintic
for sheep in combination with abamectin (ABA), to pro-
vide  broad-spectrum utility, efﬁcacy against nematodes
resistant to existing anthelmintics, and a means of pro-
tecting the new class from the rapid emergence of
anthelmintic resistance. The derquantel–abamectin com-
bination (STARTECT®, Pﬁzer Animal Health) is a solution
containing 10 mg/mL  DQL and 1 mg/mL  ABA, and is
intended for oral use in sheep at a dose of 2 mg/kg derquan-
tel  and 0.2 mg/kg abamectin.
The data reported herein were generated in a series of
studies utilising nematodes with unknown or unconﬁrmed
resistance (11 studies) or with isolates/strains having
proven single, dual, or multiple anthelmintic resistance
(eight studies). These studies were conducted across four
countries (Australia, New Zealand, South Africa and the
United  Kingdom) to support registration of DQL–ABA as an
oral  anthelmintic for sheep.
2.  Materials and methods
A  total of 19 studies utilising the controlled anthelmintic
test (Wood et al., 1995) were conducted during 2006–8 to
conﬁrm  the efﬁcacy of DQL–ABA, in the commercial for-
mulation, when administered orally to sheep at a dose
of  2 mg/kg DQL and 0.2 mg/kg ABA. The study design and
technical procedures used were consistent with the follow-
ing  regulatory guidelines: Efﬁcacy of Anthelmintics: General
Requirements (VICH GL7, 2000a); Efﬁcacy of Anthelmintics:
Speciﬁc Recommendations for Ovines (VICH GL13, 2000b);
Open access under CC BY-NC-ND license.and  WAAVP recommendations for evaluating the efﬁcacy
of  anthelmintics in ruminants (Wood et al., 1995). In addi-
tion,  all studies were conducted in accordance with Good
Clinical  Practice (VICH GL9, 2001), were subject to local eth-
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iig. 1. Chemical structure of derquantel, a spiroindole (SI) anthelmintic.
cal review, and carried out in compliance with national
nimal welfare legislation.
.1.  Experimental design
A  summary of the country, nematode stage(s) targeted,
nfection type, animal details, number of animals treated,
nd  days of necropsy for the 19 studies reported herein
re  provided in Table 1. Studies 1–11 utilised nematodes
nown to be susceptible to all anthelmintic classes, or con-
emporary ﬁeld populations of unknown or unconﬁrmed
esistance status, and targeted adult worms in Studies 1–4,
dults  and hypobiotic fourth-stage larvae (L4) in Studies
–7,  or L4 in Studies 8–11. Studies 12–19, which targeted
dults, were conducted with nematode isolates/strains
aving demonstrated single, dual, or multiple resistance
o  existing classes of anthelmintics, including macrocyclic
actones. Each study was a single site, negatively controlled,
linded efﬁcacy study, using a randomised block design,
ith  the individual animal as the experimental unit.
.2.  Experimental animals
Animal  details are provided by study in Table 1. The
heep used were Merino, Romney, Suffolk cross, Dorset
ross  and Texel cross, were 3–12 months of age, and
eighed 13.5–66.0 kg. A single sex (male or female) was
sed  in 12 of the 19 studies, while mixed sexes were used
n  the other seven. The target number of animals per exper-
mental  group was 6–14 depending on the study, although
n  a few groups an animal was removed either prior to treat-
ent  for health reasons or due to mis-dosing (if estimated
hat <90% of the intended dose was delivered).
Sheep harboured natural or experimental nematode
nfections as outlined in Table 1. For the seven natural-
nfection studies (Studies 1–3, 5–7 and 19), pre-screening
sing faecal egg counts (FECs) was conducted to ensure
 satisfactory parasite burden. Potential source ﬂocks for
hese  natural-infection studies had no known history of
nthelmintic resistance, except for unconﬁrmed benzimi-
azole (BZ) and levamisole (LEV) resistance in two  studies.
he  production systems used were considered represen-
ative of commercial sheep enterprises in the region. For
he  experimental-infection studies, the animals used were
ither  worm-naïve sheep (Studies 4 and 10–11) or sheep
reated with one or more short-acting, broad-spectrum
nthelmintics to remove existing parasite burdens (Stud-
es  8–9 and 12–18). In each of these studies, individualology 181 (2011) 180– 193
FEC were conducted prior to artiﬁcial infection to conﬁrm
freedom from gastrointestinal nematodes.
Study animals were re-located from pasture to an
indoor facility for a period of acclimatisation of approxi-
mately two  weeks before the animals were either treated
(natural-infection studies) or experimentally infected. Ani-
mals  were housed either all together as a single group or in
individual  pens; in the latter case animals in the same block
were  allocated to pens in close proximity to each other.
2.3.  Challenge method, nematode isolates/strains and
infection procedures
2.3.1.  Natural-infection studies
For Studies 1–2 and 5–7, pooled larval culture was per-
formed on pre-screening faecal samples to estimate the
proportions of nematode genera present in the ﬂock. In
general,  ﬂocks with a range of economically important gas-
trointestinal nematodes were selected, including one or
more  of: Haemonchus spp., Teladorsagia spp., Trichostrongy-
lus spp., Nematodirus spp. and Cooperia spp. In one UK study
(Study  3), Nematodirus battus was  the primary parasite of
interest,  and the source ﬂock was therefore selected on the
basis  of positive N. battus FEC; other nematode species were
also  present in this study. Study 19 used sheep harbouring
a  naturally acquired, mixed worm burden with a history
of  resistance to BZ and LEV, supplemented experimentally
with macrocyclic lactone (ML)-resistant T. circumcincta
(see Section 2.3.2).
2.3.2.  Artiﬁcial-infection studies
Studies 4 and 8–19 employed bolus inoculations of
infective third-stage larvae (L3). The method of inocula-
tion, nematode species, nematode isolate/strain, resistance
proﬁle, year acquired, larval dose, and study day of inoc-
ulation are summarised in Table 2. The worms  used for
Studies 4 and 8–11 were either reference susceptible labo-
ratory  strains or contemporary ﬁeld isolates that had been
recently  isolated and cultured in the laboratory. In Study 4,
targeting  adult H. contortus and Cooperia oncophora, infec-
tive  larvae were administered 28 days before treatment,
by oral bolus. In Studies 8–11 targeting the L4 of various
species, infective larvae were administered 5–9 days prior
to  treatment, by either oral bolus or intra-ruminal injec-
tion.  Inoculations with each genus were timed to allow
larvae to develop into L4 at the time of treatment. The infec-
tive  L3 used in Studies 12–19 were administered orally
or  intra-ruminally and were either well characterised,
anthelmintic-resistant laboratory strains or recently col-
lected,  contemporary ﬁeld isolates from farms with a
history  of anthelmintic resistance. In Study 12, a suscep-
tible reference strain of Trichostrongylus colubriformis was
also  used. For Study 19, as noted above (Section 2.3.1),
experimental infection with a ML-resistant T. circumcincta
strain was superimposed on an existing natural, mixed
infection of BZ- and LEV-resistant worms.2.4. Allocation to experimental groups
In Studies 1–7 and 12–19, faecal samples were collected
prior to treatment for individual FEC using a modiﬁed
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Table 1
Summary by study of country, nematode stage(s) targeted, infection type, animal details, number of animals treated and day/s of necropsy, in studies conducted to assess anthelmintic efﬁcacy of DQL–ABA in
sheep.
Study Country Stage targeted
(resistance status)
Infection type Animal details Animal numbers Necropsy (day/s
post  treatment)
Breed Age (months) Sex Weight
range (kg)
DQL–ABA
treated  (n)
Negative
controls (n)
Reference groups (n)
1 AUS Ad (U) N Merino 6 M 13.5–20.0 10 10 14
2 NZ Ad (U) N Romney 11–12 F 30.5–48.5  10 10 7
3 UK Ad (U) N Suffolk cross 3 M/F  20.0–35.5 6 7 14
4 UK Ad (U) E Dorset,  Suffolk &
Texel  cross
4 M/F 20.5–40.0 10 10  ABA (10) 14–15
5 RSA Ad/HL4  (U) N Merino 7 M 18.6–32.6 10 10 14–15
6  RSA Ad/HL4 (U) N Merino 3–4 M 25.8–42.6 10 10 14–15
7 UK Ad/HL4 (U) N Suffolk cross 10 M/F  24.0–49.0 14 13 13–14
8 AUS  L4 (U) E Merino 10 M 24.2–29.2 6 6 21
9 NZ L4 (U) E Romney 8–11 F 37.2–50.0 10 10 21
10 UK  L4 (U) E Texel cross 6 M/F  19.0–38.0 10 10 ABA (10) 14–15
11 UK  L4 (U) E Dorset & Suffolk
cross
6  M/F  29.0–66.0 10 10 ABA (10) 21–22
12 AUS Ad (R) E Merino 11 M 19.0–34.0 6 6 ABA (6) 13–15
13 AUS  Ad (R) E Merino 11 F 20.2–30.0 10 10 ABZ (10); LEV (10);
IVM  (10); CLO (10)
14–15
14 AUS Ad (R) E Merino 8 M 18.5–34.0 9 10 ABZ (8); LEV (9); IVM
(9);  CLO (10)
14–15
15 NZ Ad  (R) E  Romney 6–8 M 23.2–51.6 10 10 ABZ (10); LEV (9); IVM
(10)
15
16  NZ Ad (R) E Romney 7–10 F 21.0–37.6 10 10 ABZ (10); LEV (10);
IVM  (10)
14–15
17 RSA Ad  (R) E Merino 3–4  M/F 24.5–43.3  3 × 10 3 × 10 15–16
18 RSA Ad (R) E Merino 8 F 28.0–44.4 10 10 ABZ (10); LEV (10);
IVM  (10); CLO (10);
TRF  (10)
13–14
19 UK Ad (R) N/E Suffolk cross 12 M/F  36.5–60.0 10 9 FBZ (9); LEV (9); IVM
(10)
9–10
AUS, Australia; NZ, New Zealand; RSA, South Africa; UK, United Kingdom; Ad, adult; L4, fourth-stage larva; HL4, hypobiotic L4; U, unknown or unconﬁrmed resistance to anthelmintics; R, isolates/strains with
conﬁrmed  resistance to one or more anthelmintic classes; N, natural infection; E, experimental infection; N/E, natural infection supplemented with experimental infection; M,  male; F, female; DQL, derquantel;
ABA,  abamectin; ABZ, albendazole; LEV, levamisole; IVM, ivermectin; CLO, closantel; TRF, trichlorfon; FBZ, fenbendazole.
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Table 2
Summary by study of inoculation method, nematode species, nematode isolate/strain, year acquired, resistance proﬁle, larval dose and study day of
inoculation  (relative to treatment), in studies conducted to assess efﬁcacy of DQL–ABA in sheep.
Study Inoculation method Nematode species Strain name or code Year acquired Resistance proﬁle Larval dose Day of inoculation
4 Oral bolus H. contortus Leominster 2007 U 4000 −28
C.  oncophora Downs farm 2006 U 10,000 −28
8 Intra-ruminal injection Nematodirus spp. CSIRO 1981 S 3348 −9
T.  circumcincta McMaster 1950s S 8092 −7
T.  axei CSIRO 1981 S 6052 −7
H.  contortus Kirby 1983 S 3996 −5
T.  colubriformis McMaster 1950s S 6048 −5
C.  oncophora VHR 2003 U 6272 −5
9 Oral bolus T. circumcincta Manawatu 1999 BZ 5991 −7
Trichostrongylus  spp. Port  2007 U 15,061 −6
H.  contortus Ballantrae 2007 U 4035 −6
C.  curticei Ballantrae 2007 U 6147 −6
10 Oral bolus H. contortus Moredun Hco3 1950s S 4000 −6
T.  circumcincta Beulah 2006 U 6000 −6
T.  colubriformis Beulah 2006 U 5320 −6
C.  oncophora Downs Farm 2006 U 6000 −6
11 Oral bolus C. curticei Leominster 2007 U 3000 −6
T.  axei SG 2006 U 10,000 −6
12 Intra-ruminal injection H. contortus GWB2 2002 BZ/LV/ML/CL 4000 −24
T.  circumcincta Victor 2003 BZ/LV/ML 7000 −24
T.  colubriformis McMaster-S 1950s S 6000 −24
13 Intra-ruminal injection H. contortus GWB2 2002 BZ/LV/ML/CL 4000 −28
T.  circumcincta Wamiro 2002 BZ/LV/ML 8000 −28
T.  colubriformis MOX-R 2003 BZ/LV/ML 6000 −28
14 Oral bolus H. contortus Wallangra 2002 BZ/LV/ML/CL 4000 −33
T.  circumcincta Mt  Barker 2006 BZ/LV/ML 8000 −28
T.  colubriformis Arding 2005 BZ/LV 6000 −33
15 Oral bolus T. circumcincta AgR-DFL 1997 BZ/LV/ML 8230 −29/−28
T.  colubriformis Tc97 1997 BZ/LV/ML 6060 −29/−28
16 Oral bolus H. contortus ISO 2006 BZ/ML 4010 −28/−27
Teladorsagia  spp. Mixed culture 2007 BZ/ML 6070 −28/−27
Trichostrongylus  spp. Mixed culture 2007 BZ/LV/ML 10,630 −28/−27
Cooperia  spp. Mixed culture 2007 U 950 −28/−27
17 Oral bolus H. contortus Whiteriver 1984 BZ/ML/CL/TR 4000 −28
H.  contortus Kokstad 1985 BZ/LV/ML 4000 −28
H.  contortus Nooitgedacht 1995 BZ/LV/ML/CL 4000 −28
18 Oral bolus H. contortus Stutterheim 2007 BZ/LV/ML/CL 4000 −28
T.  circumcincta Streicher 1982 BZ/LV 3200 −28
19 Oral bolusa T. circumcincta Tci5 Moredun BZ/LV/ML 10,000 −23
U, unknown or unconﬁrmed resistance proﬁle; S, susceptible laboratory strain; BZ, benzimidazole; LV, levamisole; ML,  macrocyclic lactone; CL, closantel;
TR,  trichlorfon.
a This study used sheep with a naturally acquired, mixed worm burden augmented experimentally with an oral bolus of ML-resistant Teladorsagia
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cMaster method (Zajac and Conboy, 2006). Animals with
he  highest positive FEC were selected for each study,
locked by pre-treatment FEC and sex (if appropriate),
nd randomly allocated to experimental groups. In Studies
–11  targeting the L4, animals were blocked by pre-
reatment body weight and sex (if appropriate) prior to
andomisation.
.5.  Treatment administration
Prior  to treatment, all study animals were individu-
lly examined by a veterinarian and weighed for dose
alculation. Treatments administered in each study are
isted  in Table 1. Negative control animals either received placebo treatment (tap water) or were left untreated.
nimals were treated orally with DQL–ABA, placebo or a
eference anthelmintic, according to their group allocation.
QL–ABA, containing 10 mg/mL  DQL and 1 mg/mL  ABA,was  administered at a dose volume of 0.2 mL/kg to provide
doses  of 2.0 mg/kg and 0.2 mg/kg of DQL and ABA, respec-
tively. Placebo treatment was  administered at the same
dose  volume as DQL–ABA. In Studies 4, 10–16, and 18–19,
one to ﬁve additional groups, each treated with a reference
anthelmintic (selected from: albendazole, fenbendazole,
levamisole, ivermectin, abamectin, closantel and trichlor-
fon)  were included. Animals in these reference groups
received a commercial formulation of the assigned drug
at  the label dose, except in Study 14 where levamisole
was  inadvertently administered at twice the recommended
dose. No animals were treated with DQL alone in these
studies, since its anthelmintic spectrum was characterised
early in development and additional animal use to demon-
strate  this further was  not warranted. In addition, there are
no  commercial formulations of DQL, or any other spiroin-
dole  product, available. Mis-dosing occurred in a small
number of animals and in these instances the amount actu-
 ParasitoP.R. Little et al. / Veterinary
ally swallowed was estimated and recorded; no repeat or
top-up  dosing was done.
In three studies (2, 8 and 12) clinical observations
were performed by a veterinarian approximately 2 h post
treatment. In all other studies clinical observations were
performed at approximately 30 min, 2 h, 6 h and 24 h post
treatment. General health observations were conducted
daily.
2.6. Necropsy and worm counting techniques
Animals were humanely euthanised 7–22 days after
treatment depending on study (see Table 1). Organ col-
lection, parasite recovery and worm counting procedures
were in line with WAAVP recommendations (Wood et al.,
1995).  The abomasum, small intestine and, if appropri-
ate, large intestine were tied off and removed, and the
contents thoroughly washed into a suitable container. In
studies  targeting hypobiotic L4, the abomasal mucosa was
processed  separately using either a warm water soak or
mucosal  digest method. Two 5% aliquots from each of the
abomasal  contents, abomasal mucosa and small intestinal
contents, and two 10% aliquots from the large intestinal
contents, were collected. One aliquot was used for count-
ing  and identiﬁcation of parasites; the other was stored as a
back-up  sample. Prior to counting, each aliquot was  passed
over  an appropriate sized sieve to collect the nematodes of
interest.
Parasites  in each aliquot initially were identiﬁed and
counted by genus and stage. Species identiﬁcation was per-
formed  by examining adult male worms with the aid of a
high  power microscope, using standard keys. The propor-
tion  of each species, based on male worms, was applied to
the  genus count for each animal to produce an estimate
of  the total worm count for each nematode species. In the
four  experimental-infection studies (Studies 8–11) target-
ing  the L4, adult worm counts were used as the measure of
efﬁcacy,  i.e., euthanasia was timed to allow L4 present at
the  time of treatment to develop into adult worms for post
treatment worm counting.
In  Study 7, the heart and lungs were removed for recov-
ery  of respiratory nematodes. An incision was made into
the  pericardial sac and a hose inserted into the right ven-
tricle,  guided into the pulmonary artery, and tied securely.
After tying off the remaining great vessels of the heart,
the  lungs were infused with cold water, which eventually
ﬂowed out of the trachea, and the ﬁrst ﬁve litres were col-
lected  into a suitable container. Prior to identiﬁcation and
counting,  the collected washings were poured through an
appropriate sized sieve to collect any nematodes present.
While  it is now widely accepted that T. circumcincta and
Teladorsagia trifurcata are morphological variants of a sin-
gle  species, T. circumcincta (Stevenson et al., 1996), they
were  identiﬁed, counted and analysed as separate species
in  the studies reported herein, as both are still listed sepa-
rately  on anthelmintic product labels.2.7. Statistical methods and efﬁcacy calculations
In each study, the primary outcome measure was the
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compared to negative controls, for the relevant worm
species/stage. Separate analyses of worm counts were
performed for each species and lifecycle stage. A log trans-
formation [ln(x + 1)] was applied to worm count data prior
to  analysis and the transformed values were analysed using
a  general linear mixed model, including the ﬁxed effect of
treatment  group and the random effects of pen (where rel-
evant)  and block. Geometric means and corresponding 95%
conﬁdence  intervals were obtained using back transforma-
tion. Treatment differences were assessed at the 5% level of
signiﬁcance (two-tailed, P ≤ 0.05).
Each  treated group was  compared to the negative con-
trol  to estimate treatment efﬁcacy and to determine the
statistical signiﬁcance of treatment. Statistical compar-
isons between the DQL–ABA group and reference groups
were not conducted as the reference products were
included solely to establish or conﬁrm the resistance proﬁle
of  the parasites used. Geometric means were used to esti-
mate  efﬁcacy for each of the treated groups (DQL–ABA and
reference products) using the following formula, where
T01  represents the negative control group and T02 any
treated group:
%  reduction = 100×mean count (T01)−mean count (T02)
mean count (T01)
Efﬁcacy calculations were not performed for any par-
asite  species and stage where the number of infected
control animals was less than six. Resistance to reference
anthelmintics was  deﬁned as <95% reduction in geometric
worm count compared to negative control.
Statistical analyses were performed using SAS for Win-
dows version 9.1 (SAS Institute Inc, Cary, NC, USA).
3.  Results
Tables 3–5 present summaries, for Studies 1–11, of
worm count data, P-values and treatment efﬁcacies for
nematodes of the abomasum, small intestine and large
intestine, respectively. These 11 studies utilised sus-
ceptible reference isolates, or worm populations with
unknown or unconﬁrmed resistance to currently available
anthelmintics, including macrocyclic lactones, and were
intended to represent efﬁcacy of DQL–ABA against known
susceptible strains and/or contemporary nematode popu-
lations  seen in the ﬁeld. Efﬁcacy of DQL–ABA was ≥98.9%
against all species and stages of gastrointestinal nematodes
in  these studies, except for Trichuris ovis adults in Study
6  (97.0%); in the other four studies in which T. ovis was
present (Studies 1, 3, 5 and 7), efﬁcacy was ≥99.2%. In
addition, lungworms were present in Study 7 where Dicty-
ocaulus  ﬁlaria and Protostrongylus rufescens were recovered
from  the lungs of 10 of 13 and 12 of 13 negative control
animals, with geometric mean worm counts of 23.6 (range
0–458)  and 32.5 (range 0–134), respectively. Efﬁcacy of
DQL–ABA against each of these respiratory nematodes was
100%  (P < 0.0001).
Abamectin, at the standard use dose of 0.2 mg/kg,
was included as a comparison product in Studies 4, 10
and  11 (three studies where resistance to ML  and other
anthelmintics was  unknown or unconﬁrmed) to determine
if  there was  any negative interaction between DQL and
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Table 3
Summary by study of worm count data (range and geometric mean), P-values and percentage reductions for DQL–ABA administered orally at 2 mg/kg derquantel and 0.2 mg/kg abamectin against the adult, L4
and  hypobiotic L4 of abomasal nematodes of unknown or unconﬁrmed resistance status in sheep.
Species Stage Study Negative  control DQL–ABA P-value (vs. ctrl) %  Reduction
Prev Range GM Prev Range GM
Haemonchus contortus Ad 1 10/10 120–1180 333.0 0/10 0–0 0.0  <0.0001 100
2  8/10 0–1500 89.5 0/10 0–0 0.0 0.0004 100
4 10/10 940–2760 1479.3  0/10 0–0  0.0 <0.0001 100
5 10/10 1320–3600 2337.1  4/10 0–40 2.9  <0.0001 99.9
L4 8  6/6 60–3800 785.9 0/6 0–0 0.0 0.0001 100
9 10/10 180–1160 421.6  1/10 0–20 0.4  <0.0001 99.9
10  8/10 0–760 77.5 0/10 0–0 0.0 <0.0001 100
Teladorsagia circumcincta Ad 1 10/10 340–1725 755.5 1/10 0–20 0.4 <0.0001 >99.9
2 10/10  218–6854 1279.4 0/10 0–0 0.0 <0.0001 100
3 7/7 600–2460  1275.0 2/6 0–100 2.6 <0.0001 99.8
5 10/10  220–800 452.6 0/10 0–0 0.0 <0.0001 100
6 10/10 3160–11,320  6404.4 10/10 20–300 71.4 <0.0001 98.9
7  13/13 280–17,200 2575.5 1/14 0–20 0.2 <0.0001 >99.9
L4 8  6/6 4280–6200 5375.3 0/6 0–0 0.0 <0.0001 100
9 10/10 440–3855 1654.1  1/10 0–20 0.4  <0.0001 >99.9
10  10/10 240–3760 1520.4 0/10 0–0 0.0 <0.0001 100
HL4 5  10/10 140–600 298.5 0/10 0–0 0.0 <0.0001 100
7  13/13 140–3680 1203.6 1/14 0–20 0.2 <0.0001 >99.9
Teladorsagia trifurcata Ad 2 10/10 42–1306  244.8 0/10 0–0 0.0 <0.0001 100
6  10/10 440–3560 1086.2 1/10 0–60 0.5 <0.0001 >99.9
L4  9 8/10 0–540 50.0 0/10 0–0 0.0 0.0003 100
Teladorsagia spp. HL4 6 10/10 6440–19,980 11,735.8 10/10 20–800 119.0 <0.0001 99.0
Trichostrongylus axei Ad 2  10/10 1100–4260 2006.7 1/10 0–20 0.4 <0.0001 >99.9
5  8/10 0–200 42.0 0/10 0–0 0.0 0.0002 100
6 9/10 0–420 92.9  0/10 0–0 0.0  <0.0001 100
7 13/13  720–20,760 5102.7 2/14 0–40 0.6 <0.0001 >99.9
L4 8  6/6 1580–2920 2402.5 0/6 0–0 0.0 <0.0001 100
11  10/10 3060–9700 5897.4 1/10 0–40 0.4 <0.0001 >99.9
Ad, adult; L4, fourth-stage larva; HL4, hypobiotic L4; Prev, prevalence (number positive/number examined); GM,  geometric mean; DQL, derquantel; ABA, abamectin.
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Table 4
Summary by study of worm count data (range and geometric mean), P-values and percentage reductions for DQL–ABA administered orally at 2 mg/kg DQL
and  0.2 mg/kg ABA against the adult, L4 and hypobiotic L4 of small intestinal nematodes of unknown or unconﬁrmed resistance status in sheep.
Species Stage Study Negative control DQL–ABA P-value (vs. ctrl) % Reduction
Prev Range GM Prev Range GM
Cooperia curticei Ad 2 9/10 0–1426 267.6 0/10 0–0 0.0 <0.0001 100
3  6/7 0–380 88.2 0/6 0–0 0.0 0.0030 100
7 13/13 220–4360 1059.0 0/14 0–0 0.0 <0.0001 100
L4 9 10/10 500–2160 903.6 1/10 0–20 0.4 <0.0001 >99.9
11  10/10 540–1580 1055.8 0/10 0–0 0.0 <0.0001 100
Cooperia oncophora Ad 4 10/10 700–4220 2184.1 0/10 0–0 0.0 <0.0001 100
L4 10 10/10 60–4860 703.2 0/10 0–0 0.0 <0.0001 100
Cooperia surnabada Ad 2 9/10 0–14 4.4 0/10 0–0 0.0 0.0003 100
Nematodirus battus Ad 3 7/7 920–21,600 8115.8 2/6 0–40 2.1 0.0002 >99.9
Nematodirus
spathiger
Ad 1 8/10 0–380 49.6 0/10 0–0 0.0 0.0003 100
5  9/10 0–1080 128.4 0/10 0–0 0.0 <0.0001 100
6  9/10 0–2380 412.5 0/10 0–0 0.0 <0.0001 100
Nematodirus spp. HL4 6 9/10 0–300 44.8 0/10 0–0 0.0 <0.0001 100
Strongyloides papillosus Ad 2 7/10 0–200 15.0 0/10 0–0 0.0 0.0021 100
Strongyloides spp. Ad 4 10/10 60–1040 285.7 0/10 0–0 0.0 <0.0001 100
L4 11 9/10 0–560 92.8 0/10 0–0 0.0 <0.0001 100
Trichostrongylus
colubriformis
Ad 1 10/10 640–2600 1446.6 0/10 0–0 0.0 <0.0001 100
2 10/10 288–3288 1186.7 0/10 0–0 0.0 <0.0001 100
3  7/7 60–280 139.6 0/6 0–0 0.0 <0.0001 100
6 10/10 1820–12,560 5547.1 0/10 0–0 0.0 <0.0001 100
7  13/13 420–56,800 7598.7 3/14 0–60 1.2 <0.0001 >99.9
L4 8  6/6 2420–4700 3416.1 0/6 0–0 0.0 <0.0001 100
9  10/10 495–2106 955.6 0/10 0–0 0.0 <0.0001 100
10  10/10 360–3220 1836.2 0/10 0–0 0.0 <0.0001 100
Trichostrongylus
falculatus
Ad 5 10/10 320–2800 1068.5 1/10 0–40 0.4 <0.0001 >99.9
6  9/10 0–2240 522.4 0/10 0–0 0.0 <0.0001 100
Trichostrongylus rugatus Ad 6 10/10 1260–14,580 4670.6 0/10 0–0 0.0 <0.0001 100
Trichostrongylus Ad 2 10/10 432–4932 1779.9 0/10 0–0 0.0 <0.0001 100
66
mber pvitrinus L4 9 10/10 185–1844 
Ad, adult; L4, fourth-stage larva; HL4, hypobiotic L4; Prev, prevalence (nu
abamectin.
ABA in the combination product. Cooperia curticei L4 is
considered to be the dose-limiting nematode for ABA and
C.  oncophora is considered the least sensitive adult worm
for  this drug. As expected, the efﬁcacy of ABA in Studies
4,  10, and 11 was very high (≥99.1%, individual data not
shown)  against the dose-limiting and other species/stages
present, i.e., H. contortus (adult and L4), C. oncophora (adult
and  L4), T. circumcincta (L4), T. colubriformis (L4), C. cur-
ticei  (L4), and Strongyloides spp. (adult and L4). Efﬁcacy of
DQL–ABA  against the dose-limiting species/stages for ABA
was  100% in these same studies (Table 4). In one additional
study where ABA was not included (Study 9), the efﬁcacy
of  DQL–ABA against C. curticei L4 was >99.9% (Table 4).
Table 5
Summary by study of worm count data (range and geometric mean), P-values and
and  0.2 mg/kg ABA against adult large intestinal nematodes of unknown or uncon
Species Stage Study Negative control 
Prev Range GM 
Chabertia ovina Ad 2 7/10 0–122 6.3 
7  13/13 20–540 105.9 
Oesophagostomum
venulosum
Ad 6 9/10 0–40 17.1 
7  13/13 40–500 127.7 
Trichuris ovis Ad 1 10/10 30–660 128.7 
3  7/7 40–400 214.7 
5  10/10 30–90 45.4 
6 7/10  0–70 8.9 
7  11/13 0–140 31.2 
Ad, adult; Prev, prevalence (number positive/number examined); GM,  geometric9.5 0/10 0–0 0.0 <0.0001 100
ositive/number examined); GM,  geometric mean; DQL, derquantel; ABA,
These  results provide strong evidence that there is no neg-
ative  interaction between the two active ingredients in
the  combination product. Pharmacokinetic data (unpub-
lished) comparing blood levels of ABA alone, DQL alone and
the  DQL–ABA combination, also support a lack of negative
interaction between the two actives.
To assess the utility of DQL–ABA against isolates/strains
with demonstrated resistance (deﬁned herein as <95%
efﬁcacy) to one or more existing classes of anthelmintics,
including macrocyclic lactones, a series of eight stud-
ies  was  conducted (Studies 12–19; Table 1). Reference
anthelmintics were included to conﬁrm the resistance
proﬁle of the nematode isolates/strains utilised for
 percentage reductions for DQL–ABA administered orally at 2 mg/kg DQL
ﬁrmed resistance status in sheep.
DQL–ABA P-value (vs. ctrl) % Reduction
Prev Range GM
0/10 0–0 0.0 0.0119 100
0/14 0–0 0.0 <0.0001 100
0/10 0–0 0.0 <0.0001 100
0/14 0–0 0.0 <0.0001 100
1/10 0–20 0.4 <0.0001 99.7
0/6 0–0 0.0 <0.0001 100
0/10 0–0 0.0 <0.0001 100
1/10 0–10 0.3 0.0025 97.0
1/14 0–20 0.2 <0.0001 99.2
 mean; DQL, derquantel; ABA, abamectin.
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Table 6
Summary of worm count data (range and geometric mean), P-values, and percentage reductions for DQL–ABA administered orally at 2 mg/kg DQL and
0.2  mg/kg ABA against anthelmintic-resistant strains of adult Haemonchus contortus, in ﬁve studies.
Treatment Group Variable Study 12 Study 13 Study 14 Study 16 Study 18
Negative control Prevalence 6/6 10/10 10/10 9/10 10/10
Range  3640–5260 80–4360 20–1940 0–1660 800–4460
Geometric  mean 4513.3 1337.8 688.6 390.5 2896.0
DQL–ABA Prevalence 4/6 5/10 2/9 0/10 7/10
Range 0–160 0–120 0–40 0–0 0–100
Geometric  mean 13.7 5.9 1.3 0 13.4
P-value  (vs. ctrl) <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
%  Reduction 99.7 99.6 99.8 100 99.5
Albendazole Prevalence  NT 10/10 8/8 8/10 10/10
Range  60–4700 80–1720 0–320 420–4600
Geometric  mean 994.7 495.9 66.0 1909.3
P-value  (vs. ctrl) 0.6410 0.5806 0.0420 0.2075
% Reduction 25.6 28.0 83.1 34.1
Levamisole Prevalence  NT 10/10 9/9 1/10 10/10
Range  380–5280 20–160 0–20 980–4220
Geometric  mean 2170.2 73.7 0.4 2455.3
P-value  (vs. ctrl) 0.3167 <0.0001 <0.0001 0.4853
%  Reduction 0 89.3 99.9 15.2
Ivermectin (ABAa) Prevalence  6/6 10/10 9/9 8/10 10/10
Range  1060–6080 960–4960 40–1460 0–940 2120–5960
Geometric  mean 3605.4 2004.2 560.4 143.7 3690.0
P-value  (vs. ctrl) 0.4067 0.3592 0.7466 0.2425 0.2407
%  Reduction 20.1 0 18.6 63.2 0
Closantel Prevalence  NT 10/10 9/10 NT 10/10
Range  100–1840 0–920 400–3380
Geometric  mean 608.2 88.9 895.1
P-value  (vs. ctrl) 0.1397  0.0132 0.0004
%  Reduction 54.5 87.1 69.1
Trichlorfon Prevalence NT NT NT NT 9/10
Range  0–2240
Geometric  mean 165.7
P-value  (vs. ctrl) 0.0004
%  Reduction 94.3
P quantel;
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frevalence, number positive/number examined; NT, not tested; DQL, der
a Abamectin used in study 12.
hallenge in seven (Studies 12–16 and 18–19) of the
ight studies; the nematodes were either resistant
aboratory strains or contemporary ﬁeld isolates from
ocks with a history of anthelmintic resistance. In the
ighth study (Study 17), no reference anthelmintics
ere included as three well-characterised, multi-
esistant strains of H. contortus (Whiteriver, Kokstad
nd Nooitgedacht) were used to comply with regulatory
equirements and support speciﬁc efﬁcacy claims in South
frica.
Tables  6–11 present summaries, for Studies 12–19,
f worm count data, P-values and treatment efﬁcacies
gainst anthelmintic-resistant isolates/strains [Tables 6–9,
y  species, for H. contortus (5 studies), T. circumcincta (7
tudies),  T. colubriformis (5 studies) and T. trifurcata (2 stud-
es),  respectively; Table 10 for multiple species examined
n  a single study each (Nematodirus spathiger, C. curticei,
.  ovis and Trichostrongylus axei); and Table 11 for three
eference strains (Whiteriver, Kokstad and Nooitgedacht)
f H. contortus]. Where reference anthelmintics were
sed, 22 individual isolates/strains demonstrated resis-
ance  to at least one anthelmintic class (Tables 6–10), while
our  isolates/strains were fully susceptible to the refer- ABA, abamectin.
ence  anthelmintics used as well as DQL–ABA (data not
shown). Of the 22 individual nematode strains with con-
ﬁrmed  resistance to at least one reference anthelmintic,
three were resistant to one class (two to BZ and one
to  ML), eleven were resistant to two  classes (four to
BZ/LEV and seven to BZ/ML), ﬁve were resistant to
three classes (BZ/LEV/ML), two were resistant to four
classes (BZ/LEV/ML/closantel), and one was resistant to ﬁve
anthelmintic classes (BZ/LEV/ML/closantel/trichlorfon); 16
isolates/strains demonstrated resistance to the ML  used
(ivermectin or ABA). The GWB2 strain of H. contortus was
used  in two separate studies, and found to be resistant to
both  ABA (efﬁcacy 20.1%, Study 12) and ivermectin (efﬁ-
cacy  0%, Study 13). Although no reference anthelmintics
were used in Study 17 conducted in South Africa, the
three anthelmintic-resistant strains of H. contortus have
been  previously characterised. The Whiteriver strain was
isolated  in 1984 and is resistant to ivermectin, closan-
tel, fenbendazole, trichlorfon and rafoxanide (van Wyk
et  al., 1989a); the Nooitgedacht strain was isolated in
1985  and is resistant to ivermectin, levamisole, meben-
dazole and closantel (Dr PC van Schalkwyk, pers. com.);
while the Kokstad strain was  isolated in 1995 and is resis-
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Table 7
Summary of worm count data (range and geometric mean), P-values and percentage reductions for DQL–ABA administered orally at 2 mg/kg DQL and
0.2  mg/kg ABA against anthelmintic-resistant strains of adult Teladorsagia circumcincta, in seven studies.
Treatment group Variable Study 12 Study 13 Study 14 Study 15 Study 16 Study 18 Study 19
Negative control Prevalence 6/6 10/10 10/10 10/10 10/10 10/10 9/9
Range  1260–4780 60–1760 500–4260 120–3024 17–2934 240–620 2440–9600
Geometric  mean 2863.0 600.6 1641.3 1284.4 681.4 385.7 5322.7
DQL–ABA Prevalence 1/6 4/10 5/9 0/10 4/10 0/10  0/10
Range 0–140 0–120 0–100 0–0 0–333 0–0 0–0
Geometric  mean 1.3 3.3 7.8 0 5.1 0 0
P-value  (vs. ctrl) <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
%  Reduction >99.9 99.5 99.5 100 99.3 100 100
Albendazole
(Fenbendazolea)
Prevalence  NT 10/10 8/8 10/10 10/10 10/10 9/9
Range  340–1580 800–3640 80–3708 147–1145 120–480 1820–15,240
Geometric  mean 836.6 1936.2 1662.6 360.6 275.1 4344.1
P-value  (vs. ctrl) 0.3527 0.6153 0.6457 0.2607 0.5376 0.7097
%  Reduction 0 0 0 47.1 28.7 18.4
Levamisole Prevalence  NT 10/10 9/9 7/9 7/10 8/10 7/9
Range 80–740 60–520 0–1020 0–160 0–180 0–1280
Geometric  mean 332.1 177.5 65.8 15.2 21.6 44.3
P-value  (vs. ctrl) 0.1314 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
%  Reduction 44.7 89.2 94.9 97.8 94.4 99.2
Ivermectin (ABAb) Prevalence 6/6 10/10 9/9 10/10 10/10 5/10 10/10
Range  20–1940 100–920 40–1260 680–3600 140–3192 0–60 200–3840
Geometric  mean 274.9 299.6 632.0 1839.4 914.2 4.7 1273.1
P-value  (vs. ctrl) 0.0046 0.0834 0.0509 0.5230 0.6201 <0.0001 0.0103
%  Reduction 90.4 50.1 61.5 0 0 98.8 76.1
Trichlorfon Prevalence  NT NT NT NT NT 9/10 NT
Range 0–320
Geometric  mean 48.7
P-value (vs. ctrl) 0.0004
% Reduction 87.4
Prevalence, number positive/number examined; NT, not tested; DQL, derquantel; ABA, abamectin.
a Fenbendazole used in study 19.
b Abamectin used in study 12.
Table 8
Summary of worm count data (range and geometric mean), P-values and percentage reductions for DQL–ABA administered orally at 2 mg/kg DQL and
0.2  mg/kg ABA against anthelmintic-resistant strains of adult Trichostrongylus colubriformis, in ﬁve studies.
Treatment group Variable Study 13 Study 14 Study 15 Study 16 Study 19
Negative control Prevalence  9/10 10/10 10/10 10/10 7/9
Range  0–6640 420–3340 3040–5740 4250–6228 0–4780
Geometric mean 646.8 1586.8 4077.9 5070.6 196.9
DQL–ABA Prevalence 4/10 2/9 0/10 1/10 1/10
Range  0–100 0–20 0–0 0–20 0–20
Geometric mean 3.5 1.0 0 0.4 0.4
P-value  (vs. ctrl) <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
%  Reduction 99.5 99.9 100 >99.9 99.8
Albendazole
(Fenbendazolea)
Prevalence 10/10  8/8 10/10 10/10 7/9
Range  20–3700 1040–3420 1320–2660 2600–5160 0–2080
Geometric mean 563.8 2050.0 1772.3 3770.7 86.6
P-value  (vs. ctrl) 0.8917 0.3175 <0.0001 0.0001 0.4181
%  Reduction 12.8 0 56.5 25.6 56.0
Levamisole Prevalence 6/10 9/9 9/9 10/10 4/9
Range  0–540 260–2180 300–1500 2120–5800 0–2480
Geometric mean 28.2 898.7 559.5 4135.6 12.6
P-value  (vs. ctrl) 0.0034 0.0652 <0.0001 0.0700 0.0111
%  Reduction 95.6 43.4 86.3 18.4 93.6
Ivermectin Prevalence 9/10  3/9 10/10 10/10 0/10
Range  0–6820 0–100 400–4060 3140–5920 0–0
Geometric mean 666.7 3.0 1500.5 4440.5 0
P-value  (vs. ctrl) 0.9760 <0.0001 <0.0001 0.0658 <0.0001
%  Reduction 0 99.8 63.2 12.4 100
Prevalence, number positive/number examined; DQL, derquantel; ABA, abamectin.
a Fenbendazole used in Study 19.
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Table 9
Summary of worm count data (range and geometric mean), P-values and percentage reductions for DQL–ABA administered orally at 2 mg/kg DQL and
0.2  mg/kg ABA against anthelmintic-resistant strains of adult Teladorsagia trifurcata, in two studies.
Treatment group Variable Study 15 Study 16
Negative control Prevalence  9/10 9/10
Range  0–522 0–926
Geometric  mean 114.9 79.5
DQL–ABA Prevalence 0/10 4/10
Range  0–0 0–112
Geometric  mean 0 3.3
P-value  (vs. ctrl) <0.0001 0.0025
%  Reduction 100 95.9
Albendazole Prevalence  7/10 8/10
Range  0–712 0–172
Geometric  mean 59.3 37.7
P-value  (vs. ctrl) 0.4875 0.4293
%  Reduction 48.4 52.6
Levamisole Prevalence  4/9 4/10
Range  0–180 0–40
Geometric  mean 5.0 1.2
P-value  (vs. ctrl) 0.0039 <0.0001
%  Reduction 95.7 98.5
Ivermectin Prevalence  7/10 10/10
Range  0–459 64–608
Geometric  mean 45.2 247.3
P bamecti
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%  Reduction 
revalence, number positive/number examined; DQL, derquantel; ABA, aant to benzimidazoles, ivermectin and levamisole (Neveu
t  al., 2007; Mottier and Prichard, 2008). As detailed in
ables  6–11, efﬁcacy of DQL–ABA was ≥99.3% against all
f  the anthelmintic-resistant nematodes, including those
able 10
ummary of worm count data (range and geometric mean), P-values and perce
.2  mg/kg ABA against anthelmintic-resistant strains of Nematodirus spathiger, Co
Treatment group Variable Study 16 
Nematodirus spathiger 
Negative control Prevalence 10/10 
Range 20–180 
Geometric mean 72.6 
DQL–ABA Prevalence 1/10 
Range 0–20 
Geometric mean 0.4 
P-value (vs. ctrl) <0.0001 
%  Reduction 99.5 
Albendazole
(Fenbendazolea)
Prevalence 10/10 
Range 20–140 
Geometric mean 50.8 
P-value (vs. ctrl) 0.3013 
%  Reduction 30.1 
Levamisole Prevalence 2/10 
Range 0–40 
Geometric mean 1.0 
P-value (vs. ctrl) <0.0001 
%  Reduction 98.7 
Ivermectin Prevalence 6/10 
Range 0–60 
Geometric mean 7.4 
P-value (vs. ctrl) 0.0014 
%  Reduction 89.7 
revalence, number positive/number examined; DQL, derquantel; ABA, abamecti
a Fenbendazole used in Study 19.0.3300 0.1272
60.6 0
n.resistant  to ML,  in Studies 12–19 with a single exception
(efﬁcacy against T. trifurcata was 95.9% in Study 16).
Where assessed, mild transient coughing occurred
immediately post dosing in 102 out of 166 animals treated
ntage reductions for DQL–ABA administered orally at 2 mg/kg DQL and
operia curticei, Trichuris ovis, and Trichostrongylus axei in one study each.
Study 19 Study 19 Study 19
Cooperia curticei Trichuris ovis Trichostrongylus axei
8/9 7/9 9/9
0–2440 0–240 220–12,820
250.7 31.7 2409.8
0/10 0/10 0/10
0–0 0–0 0–0
0 0 0
<0.0001 <0.0001 <0.0001
100 100 100
6/9 5/9 8/9
0–2660 0–160 0–11,520
112.6 9.1 1145.7
0.3922 0.1099 0.4732
55.1 71.3 52.5
3/9 5/9 7/9
0–520 0–40 0–1460
4 4.8 34.3
0.0002 0.0208 0.0002
98.4 85.0 98.6
0/10 1/10 6/10
0–0 0–60 0–3200
0 0.5 15.2
<0.0001 <0.0001 <0.0001
100 98.4 99.4
n.
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Table 11
Summary of worm count data, P-values and percentage reductions for DQL–ABA administered orally at 2 mg/kg DQL and 0.2 mg/kg ABA against three
anthelmintic-resistant reference strains of Haemonchus contortus in Study 17.
Strain of H. contortus Negative control DQL–ABA P-value (vs. ctrl) % Reduction
Prevalence Range Geometric mean Prevalence Range Geometric mean
Whiteriver 10/10 900–3540 2100.5 0/10 0–0 0.0 <0.0001 100
Kokstad 10/10 740–2340 1568.9 1/10 0–20 0.4 <0.0001 >99.9
0/10 
bamectiNooitgedacht 10/10 320–4180 2406.2 
Prevalence, number positive/number examined; DQL, derquantel; ABA, a
with DQL–ABA, compared to 5 out of 59 for ivermectin, 3
out  of 30 for abamectin, 1 out of 30 for closantel, 2 out of
10  for trichlorfon, and 1 out of 166 for placebo (water).
No coughing occurred in animals treated with albenda-
zole, fenbendazole or levamisole. No other adverse events
occurred in any treatment group in any study.
4. Discussion
The status of anthelmintic resistance in small rumi-
nants has been reviewed (Besier and Love, 2003; Kaplan,
2004; Jabbar et al., 2006) and what is particularly alarm-
ing  is the rapidly escalating level of resistance to the
macrocyclic lactones, as well as reports of dual, triple and
multiple  resistance to available anthelmintic classes (van
Wyk  et al., 1989a, 1999; Wooster et al., 2001; Love et al.,
2003;  Yue et al., 2003; Bartley et al., 2004, 2005; Hughes
et  al., 2005, 2007; Waghorn et al., 2006; Sargison et al.,
2007;  Sutherland et al., 2008; Wrigley et al., 2006). The
cost  of anthelmintic resistance to individual sheep produc-
ers  and to national sheep industries has been estimated by
several  authors. A trial conducted in the southern sheep
producing zone of Western Australia, in Merino weaners,
estimated that production losses associated with using an
ineffective  anthelmintic compared to a fully effective one,
would  be over A$2 per weaner in wool returns and over
A$4  per weaner in animal value in a 12-month period.
Signiﬁcantly, the same trial conﬁrmed that anthelmintic
resistance is largely an ‘invisible’ problem, as the cost to
production resulting from the ineffective drenches would
not  have been detected without comparison to sheep
treated with the fully effective one (Besier et al., 1996). A
report  published by Meat and Livestock Australia (Sackett
et  al., 2006) estimated the losses due to internal para-
sites to be A$369 million per annum. In New Zealand,
Leathwick (2004) conducted an analysis that estimated the
cost  of anthelmintic resistance in 2002 to be NZ$18 mil-
lion  per annum, increasing to NZ$60 million over the next
20  years. The analysis estimated that the total discounted
cost accumulated over the next 30 years would exceed
NZ$1.3 billion. The economic impact of uncontrolled par-
asitism  is exempliﬁed where resistance to all available
broad-spectrum anthelmintics resulted in the closure of
some  individual farms in the UK (Sargison et al., 2005; Blake
and  Coles, 2007) and earlier in South Africa (van Wyk  et al.,
1989a,b).Administration of effective anthelmintics in combina-
tion has been suggested as a potential means of slowing
or  delaying the development of anthelmintic resistance
(Anderson et al., 1988, 1991; McKenna, 1990; Smith, 1990;0–0 0.0 <0.0001 100
n.
Coles  and Roush, 1992; Barnes et al., 1995; Leathwick et al.,
2009).  This strategy has been endorsed by a group of Aus-
tralian  parasitologists as the foremost means of delaying
anthelmintic resistance, by keeping resistant alleles as rare
as  possible (Dobson et al., 2001). The discovery of DQL,
a  semi-synthetic derivative of paraherquamide, and its
development with ABA in a combination product provides
just  such a new tool to control parasites of sheep, includ-
ing  those resistant to currently available anthelmintics.
Derquantel–abamectin is the ﬁrst combination product
containing a new active that has not been previously used
as  a standalone anthelmintic, and therefore there is no pre-
existing  selection of resistant worms; this contrasts with
other  combinations that have generally been developed
to  manage existing or emerging resistance problems. The
maintenance of free-living strains of susceptible worms in
refugia  is also an important strategy in delaying resistance
development (van Wyk, 2001; Besier, 2006; Leathwick
et al., 2009). Indeed, the use of highly effective combi-
nations relies on a portion of the worm population, L3
on  pasture, escaping selection by the anthelmintic and
thus  providing a source of susceptible genes, even if a
small  number of worms  survive the combination treat-
ment  (Dobson et al., 2001). Inclusion in the combination of
ABA,  which has a mechanism-of-action distinct from that
of  DQL, should help to minimise selection for resistance to
DQL.  Thus, DQL–ABA provides a signiﬁcant opportunity for
sheep  producers to use a new combination drench while
the  genes for resistance are rare-one of the conditions iden-
tiﬁed  for combinations to be highly effective in slowing the
development of resistance (Dobson et al., 2001; Leathwick
et  al., 2009). The prudent use of a highly effective com-
bination anthelmintic such as DQL–ABA, combined with
sustainable drenching practices that maintain a proportion
of  susceptible worms in refugia, should be a cornerstone of
sustainable  parasite control in the future.
Though derquantel is not fully effective on its own
against T. circumcincta, the combination of DQL and ABA
demonstrated excellent activity in controlling both suscep-
tible  (Table 3) and ML-resistant (Table 7) isolates/strains
of this parasite. Further work is required to understand
the nature of this high efﬁcacy of DQL–ABA against
ML-resistant strains of T. circumcincta. Interestingly, Gill
and  Lacey (1993) noted that the related molecule, para-
herquamide, was  10-fold more potent against ML-resistant
than ML-sensitive worms.The results from the studies reported herein conﬁrm
the high therapeutic efﬁcacy of DQL–ABA. Used orally at
a  dose of 2 mg/kg DQL and 0.2 mg/kg ABA, this combina-
tion anthelmintic controlled a broad range of economically
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mportant gastrointestinal and respiratory nematode par-
sites  of sheep, regardless of resistance status, as follows:
98.9% efﬁcacy against H. contortus (adult and L4); T. cir-
umcincta (adult, L4 and hypobiotic L4); T. trifurcata (L4);
.  axei (adult and L4); T. colubriformis (adult and L4);
richostrongylus falculatus (adult); Trichostrongylus ruga-
us  (adult); Trichostrongylus vitrinus (adult and L4); C.
urticei  (adult and L4); C. oncophora (adult and L4); N.
pathiger (adult); N. battus (adult); Nematodirus spp. (hypo-
iotic  L4); Strongyloides papillosus (adult); Strongyloides
pp. (L4); Chabertia ovina (adult); Oesophagostomum venu-
osum  (adult); D. ﬁlaria (adult); and P. rufescens (adult);
97.0% efﬁcacy against T. ovis (adult); and ≥95.9% efﬁ-
acy  against T. trifurcata (adult). Derquantel–abamectin
ill provide an important new tool for the control of nema-
ode  parasites of sheep, including strains with resistance to
xisting  anthelmintic classes.
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